IMMIX BIOPHARMA, INC. IMMX 深 滬
等待開盤 09-12 09:30:00 美东时间
2.22
+0.030
+1.37%
華盛通- 最 高2.3047
- 今 開2.20
- 成交量 12.43万股
- 最 低 2.15
- 昨 收 2.19
- 總市值 6401.17万
- 52周最高 3.20
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 1.26
- 委 比 89.62%
- 總股本 2883.41万
- 歷史最高 8.68
- 量 比 0.93
- 振 幅 7.06%
- 歷史最低 0.68
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Dr. Nancy T. Chang, former CEO of Tanox, Inc., joins Immix Biopharma's board and Goose Capital investment. She led XOLAIR® and other successful drugs to market, generating over $5 billion in sales. Immix Biopharma is advancing NXC-201, a CAR-T therapy for AL Amyloidosis, with promising clinical results and designation as RMAT and ODD.
09-11 13:15
Immix Biopharma Completes Private Placement Transaction
The latest announcement is out from Immix Biopharma ( ($IMMX) ). On September 5...
09-09 04:36
Immix Biopharma Gains Strategic Investment From Goose Capital And Dr. Nancy T. Chang; Financial Terms Not Disclosed
Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received
09-09 04:08
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Immix Biopharma, a clinical-stage biopharma company developing cell therapies for AL Amyloidosis and other serious diseases, has received strategic investment from Goose Capital and Dr. Nancy T. Chang, former CEO of Tanox. Dr. Chang’s expertise includes developing FDA-approved drugs like XOLAIR® and EBGLYSS®, generating over $5B in sales. Goose Capital, focusing on breakthrough technologies, supports Immix’s mission to cure incurable diseases. Im...
09-08 20:05
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio") will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference on November 11-13, 2025, in New York, NY. The Company will offer one-on-one meetings for interested investors, who should contact their Stifel representative to request meetings. A replay link will be available on the Immix website. ImmixBio is developing NXC-201, a st...
08-25 13:30
Immix Biopharma Advances NXC-201 Cell Therapy In AL Amyloidosis And Other Serious Diseases; Plans To Out-License OSD Programs
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –– Company plans to partner-out Other Serious Disease programs –– On track for first Biologics License Application (BLA) approved cell
08-07 00:32
Immix Biopharma Announces Other Serious Diseases Strategy
Immix Biopharma announced updates on its CAR-T cell therapy NXC-201, which is being developed for relapsed/refractory AL Amyloidosis and has shown promise in treating other serious diseases. The company plans to partner out its Other Serious Disease (OSD) programs while advancing NXC-201 toward a Biologics License Application (BLA) for its lead indication. NXC-201 features a "digital filter" to reduce non-specific activation and has received RMAT...
08-06 16:30
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
<p>Immix Biopharma has reported a strong safety profile for its CAR-T therapy NXC-201, with no neurotoxicity observed in low-volume disease cases. The company is advancing toward submitting a Biologics License Application (BLA) for NXC-201 in relapsed/refractory AL Amyloidosis, a rare condition causing organ damage. NXC-201 has received FDA's Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation. The company aims to expand NXC...
07-11 13:36
Immix Biopharma Accelerates U.S. NEXICART-2 Clinical Trial In Relapsed/Refractory AL Amyloidosis; Says It Is On Track For First BLA Approved Cell Therapy In Unaddressed Orphan Indication
– National Footprint of NEXICART-2 Trial Sites Expanded –– On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication –– NEXICART-2 interim results were
07-07 21:37
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Immix Biopharma expands NEXICART-2 clinical trial sites to 18 in the U.S., aiming to address unmet needs in relapsed/refractory AL Amyloidosis. NEXICART-2 interim results were presented at ASCO 2025. The company is on track for FDA BLA submission for its CAR-T therapy NXC-201, which has orphan drug designation and RMAT designation. AL Amyloidosis affects up to 33,277 patients in the U.S. with a growing prevalence of 12% annually.
07-07 13:35
